Display options
Cite
Ota S, Hara Y, Kanoh S, et al. Acute eosinophilic pneumonia caused by camostat mesilate: The first case report. Respir Med Case Rep. 2016;19:21-3doi: 10.1016/j.rmcr.2016.06.005.
Ota, S., Hara, Y., Kanoh, S., Shinoda, M., Kawano, S., Fujikura, Y., Kawana, A., & Shinkai, M. (2016). Acute eosinophilic pneumonia caused by camostat mesilate: The first case report. Respiratory medicine case reports, 1921-3. https://doi.org/10.1016/j.rmcr.2016.06.005
Ota, Shinichiro, et al. "Acute eosinophilic pneumonia caused by camostat mesilate: The first case report." Respiratory medicine case reports vol. 19 (2016): 21-3. doi: https://doi.org/10.1016/j.rmcr.2016.06.005
Ota S, Hara Y, Kanoh S, Shinoda M, Kawano S, Fujikura Y, Kawana A, Shinkai M. Acute eosinophilic pneumonia caused by camostat mesilate: The first case report. Respir Med Case Rep. 2016 Jun 16;19:21-3. doi: 10.1016/j.rmcr.2016.06.005. eCollection 2016. PMID: 27408783; PMCID: PMC4925915.
Copy Download .nbib Format: NLM
Share it on

Respir Med Case Rep. 2016 Jun 16;19:21-3. doi: 10.1016/j.rmcr.2016.06.005. eCollection 2016.

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report.

Respiratory medicine case reports

Shinichiro Ota, Yu Hara, Soichiro Kanoh, Masahiro Shinoda, Shuichi Kawano, Yuji Fujikura, Akihiko Kawana, Masaharu Shinkai

Affiliations

  1. Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
  2. Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan; Respiratory Disease Center, Yokohama City University Medical Center, Kanagawa, Japan.
  3. Respiratory Disease Center, Yokohama City University Medical Center, Kanagawa, Japan.

PMID: 27408783 PMCID: PMC4925915 DOI: 10.1016/j.rmcr.2016.06.005

Abstract

Camostat mesilate is in widespread clinical use mainly to treat chronic pancreatitis, and drug-induced lung injury has not been previously reported. However, pulmonary infiltration with peripheral blood eosinophilia appeared after taking camostat mesilate for ten days. The histological findings showed eosinophilic infiltration into the alveolar space and interstitum, and drug lymphocyte stimulation test of peripheral blood was positive. Both peripheral blood eosinophilia and pulmonary involvements improved two weeks later with the cessation of this drug. To the best of our knowledge, this case is the first report of camostat mesilate-induced acute eosinophilic pneumonia.

Keywords: BALF, bronchoalveolar lavage fluid; Camostat mesilate; DLST, drug lymphocyte stimulation test; Drug cessation; Drug lymphocyte stimulation test; Drug-induced lung injury; Eosinophilic pneumonia; GGO, ground glass opacities; HRCT, High-resolution computed tomography

References

  1. Antimicrob Agents Chemother. 1996 Apr;40(4):934-40 - PubMed
  2. J Thorac Imaging. 1991 Jan;6(1):1-7 - PubMed
  3. Am Rev Respir Dis. 1986 Feb;133(2):321-40 - PubMed
  4. Am Rev Respir Dis. 1986 Mar;133(3):488-505 - PubMed
  5. Allergy. 2004 Aug;59(8):809-20 - PubMed
  6. Tohoku J Exp Med. 2007 May;212(1):49-53 - PubMed
  7. Chest. 2008 Nov;134(5):1027-32 - PubMed
  8. Clin Chest Med. 2004 Mar;25(1):77-88 - PubMed
  9. Radiographics. 2000 Sep-Oct;20(5):1245-59 - PubMed
  10. Br J Cancer. 2004 Aug;91 Suppl 2:S24-30 - PubMed

Publication Types